Lawrence Blatt, Aligos CEO

Ali­gos chops off a he­pati­tis B pro­gram — again — af­ter a pa­tient was briefly hos­pi­tal­ized

Ali­gos is fac­ing an­oth­er set­back af­ter a Phase I study missed the mark and re­vealed safe­ty is­sues for an an­ti­sense chron­ic he­pati­tis B pro­gram. And it’s spurring a broad­er in­ter­nal shift.

The biotech an­nounced Tues­day it will dis­con­tin­ue de­vel­op­ment of ALG-020572 af­ter a chron­ic he­pati­tis B pa­tient was sent to the hos­pi­tal to treat an ad­verse event. Ali­gos said the sub­ject ex­pe­ri­enced a “sig­nif­i­cant in­crease in ala­nine amino­trans­ferase” af­ter mul­ti­ple dos­es and was one of four pa­tients to see po­ten­tial­ly drug-re­lat­ed ALT flares in this co­hort.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA